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 INTRODUCTION 
 Lipoprotein (a) has been identified as a major risk factor of atherosclerosis 
in non - diabetic and diabetic patients. It is a well known fact that diabetic patients 
have a high risk of cardiovascular disease; Lp(a) has been recognized as the high 
risk factor of the above disease in diabetic patients. 
 Lp(a) is an LDL-like particle to which apolipoprotein(a) [apo(a)] is 
attached through a disulfide bond to apolipoprotein B100 [apoB100]. Genetic 
variation of the Lp(a) genes is the main determinant of Lp(a) serum levels but non 
genetic factors could also affect its concentration. Several studies have shown the 
influence of diet, drugs and hormones on Lp(a) levels. There are several studies 
that evaluated the relationship between Lp(a) and glycaemic control in diabetic 
patients but little is known about the influence of lipid profiles on serum Lp(a) 
concentration. Some authors have found a positive correlation between serum 
levels of Lp(a) and LDL cholesterol in non - diabetic patients. There is also a 
negative correlation between Lp(a) and triglycerides that has been reported in 
nondiabetic subjects, but there are no specific studies on this issue in the diabetic 
population. 
 Hence with a keen interest to determine the relationship between Lp(a) and 
other lipid parameters in Normal and Type 2 Diabetic subjects in our part of the 
country this work has been taken up for the study. 
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 REVIEW OF LITERATURE 
 Lipoprotein (a) [Lp(a)] was detected in 1963 by Kareberg in Norway in a 
study designed to detect antigenic variation in Human LDL. He could distinguish 
between so called Lpa +ve and Lpa -ve serums and demonstrated Autosomal 
Dominant inheritance of Lp(a) trait using antibodies raised in rabbits against 
human lipoprotein preparation. Shortly it became apparent that Lp(a) by itself is a 
distinct particle rather than an allelic variant of LDL(17,18,19,20). 
 As Lp(a) was rediscovered several times, several names like "SINKING  
PRE  β  LIPOPROTEIN"(21),  "PRE  β  LIPOPROTEIN"(22),  "LDL a-1" or just 
"A NEW ATYPICAL LIPOPROTEIN" have been attributed to it(17,19,23). 
 A breakthrough in the research  of  the  lipoprotein  was  when  Mclean et 
al., in 1987 cloned and sequenced one of its components apo(a) which revealed a 
high degree of homology to plasminogen(17,19,24,25). Lipoprotein(a) has been 
identified as a major risk factor of atherosclerosis in non diabetic and diabetic 
patients(1,2) due to this component apo(a). 
STRUCTURE OF Lp(a) 
 Lipoprotein(a) [Lp(a)] is a low density lipoprotein (LDL) like particle 
formed by the association of the highly polymorphic glycosylated 
apolipoprotein(a) [apo(a)] through a disulphide bond with apolipoprotein B100 
(apoB100)(3), the classic protein moiety of LDL(26). Lp(a) is found to be spherical 
with the size of 4 million daltons and a diameter of 250 AE(3). Lipoprotein(a) has a 
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density from 1.040 to 1.30 g/ml(19). In Agarose gel electrophoresis, Lp(a) moves 
as a single band between LDL and VLDL(19,40). Genetic variation of the Lp(a) 
genes is the main determinant of Lp(a) serum levels but non - genetic factors like 
diet, drugs and hormones(5,6,7,8) could also affect its concentration. The schematic 
structure of lipoprotein(a) is given in Figure No.1. 
 Although apo(a) transcripts have recently been found in adrenal glands, 
lungs, pituitary, brain and testes(31), it is mainly synthesized by the liver as a 
precursor with lower molecular mass which is processed into the mature form and 
then secreted into the blood stream(32). After secretion, free apo(a) binds rapidly to 
circulating LDL's to generate complete Lp(a) particles(33).  The  assembly  of  
Lp(a)  as  per  the  study  of  Rath  M  Niedorf  et al.,(62) is produced in the 
endoplasmic reticulum of liver though in another study by Lobentanz EM et al 
Lp(a) was hypothesized to be assembled almost exclusively extracellularly, as no 
apo(a) - apo B100 complexes were detected by them within cells(32). 
 The composition and physiochemical properties of the lipoprotein remnant 
known as Lpa -ve (Chart No.1) derived after dissociation of apo(a) from Lp(a) by 
chemical reduction has made clear that Lp(a) can be considered as a genetically 
determined variant of LDL increased in density and size. Lp(a) belongs to the 
heterogenous family of cholesterol enriched lipoprotein. Cholesterol in either free 
or esterified form represents almost 40% of its mass. The relative weight of 
phospholipids (17-24%) is comparable to that of proteins (17-29%) whereas the 
triglyceride content is rather limited, usually below 9%(34,39). Almost 23% of the 
apo(a) mass is attributable to N and O glycosides producing the remarkable 
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electronegative potential of the lipoprotein particle [Lp(a)](37). 
 About 90% of Lp(a) concentration is under genetic regulation. The greatest 
part of the variability in Lp(a) levels (over 40%) is accounted for by quantitative 
polymorphism in the internal sequence of the apo(a) gene. Qualitative 
polymorphism in the sequence of the promoter play only a minor role (from 10 to 
14%)(41). Despite this genetic regulation, some metabolic abnormalities may have 
effect on Lp(a) levels in plasma(42,43). Among these acute phase response, 
hormonal homeostasis, diabetes, liver and renal failure and defects in the LDL 
receptor gene have all been shown to influence the still enigmatic metabolism of 
this lipoprotein. 
 Lp(a) has been attributed a polymorphic structure, the reasons for which 
are enumerated below : 
 1. The composition of Lp(a) and its lipid contents 
 2. The structure of apo(a) 
  a. Size polymorphism of apo(a) 
  b. Sequence polymorphism of apo(a) 
1. COMPOSITION OF Lp(a) AND ITS LIPID CONTENTS 
 Lp(a) is a complex assembled from two different components which forms 
the central and outer core(17,19,40). The central core which is hydrophobic is formed 
by LDL. The lipid fraction of LDL is constituted by esterified cholesterol, 
phospholipid, triglycerides, free cholesterol and apoB100, its protein fraction. The 
structure of Lipoprotein(a) is shown in Figure No.2. 
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 The outer core of Lp(a) is found to be apo(a) which is hydrophilic 
glycoprotein with a uniquely high degree of conserved internal repeat structure 
and an enormous size heterogenicity(19,40). Hence while LDL contains only 
apoB100, Lp(a) contains both apo B100 and apo(a). In other words Lp(a) differs 
from LDL mainly by addition of the large glycoprotein apo(a) which is bound to 
apoB 100 by disulphide linkage(19).  
 In some subject Lp(a) contains 2 molecules of apo(a) per molecule of apo 
B 100. In such cases, the density of Lp(a) depends not only on size of apo(a) but 
also on its number(19,44). 
 G.Lippi and G. Guidi have made evident in their Table (Chart No.1) where 
they have compared Lp(a) and LDL that the two molecules are not identical 
because Lp(a) is much large with a greater protein content and higher density than 
LDL. 
2. STRUCTURE OF Apo(a) 
 This is a glycoprotein with varying degrees of glycosylation 
(approximately 35% by weight). The carbohydrate fraction is constituted by sialic 
acid and "N" and "O" linked carbohydrate chains where N-Acetyl glucosamine is 
the principal "N" linked sugar. Its molecular mass is about 230 - 280 kDa 
(kilodaltons). Apo(a) is composed of a kringle containing domain and a serine 
protease domain(45,46,47,48,49) as shown in Figure No.3. 
 The basic modular units of apo(a) are the structures called kringles which 
are sequences of 80 - 90 aminoacids. They are non catalytic cysteine rich 
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internally looped structures with the shape of a "Pretzel". As the shape resembles 
a danish cake called kringle the basic units of apo(a) have been named so. These 
kringles (k) are internally stabilized by 3 cross linking disulphide bridges(17,19) as 
illustrated in Figure No.4. 
 The kringle structures has been discovered not only in apo(a) but also in 
certain other protein molecules namely plasminogen, tissue plasminogen activator 
(t-PA), urokinase, prothrombin, protein C, coagulation factors VII, IX, X, 
XIII(17,19). Though the kringles in the above enumerated proteins are of 5 types 
referred to by Roman numerals I-V, apo(a) contains only 2 types of kringles 
namely type IV and V(17,18,19). Each kringle structure of apo(a) contains a potential 
"N" linked glycosylation site formed by Asp-Leu-Thr(17). 
 As the number of times a specific kringle is repeated identically in a 
protein molecule it is represented by Arabic Numerals. The  repetition  of  36-40 
times of type IV kringle in apo(a) is represented as KIV(n) where (n) represents 
the number of units of KIV. The kringles are serially numbered from 1-37 from 
the NH2 terminal end of apo(a). It is to be noted that out of the 37 kringles, the 
kringle with serial number 1-36 are of KIV which is followed by a single kringle 
of Type V serial No.37(19,20). 
 Among the kringles in KIV, 10 basic types designated KIV type 1-10 are 
seen in apo(a) which are similar to each other but not identical to each other. All 
the types present in apo(a) are  all  in  a  single  copy  except  KIV Type 2 which 
is present in a variable number of copies ranging from 3-40. The varying number 
of KIV Type 2 repeat is said to be a major determinant of apo(a) size 
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heterogenicity giving origin to a large number of apo(a) isoforms(20,25,49). 
 The KIV repeats of apo(a) is followed by a single KV. Thus the whole 
kringle domain of KIV repeat and KV of apo(a) contains together 11 different 
type of kringles out of which only KIV type 10 contains all the key interactive 
aminoacids to bind to lysine of fibrin and thereby interferes with the similar 
function of plasmin involved in fibrinolysis. Interindividual differences in the 
aminoacid sequences of apo(a) KIV Type 10 are also known to exist(19). It is also 
said that the penultimate KIV present at the carboxyterminal of apo(a) has an 
unpaired cysteine residue that favours the disulphide bond formation with the 
cysteine residue in apoB100(17). 
 As reviewed already kringle structures is common to several proteins 
which are considered to be members of a protein superfamily and are found to be 
regulatory proteins in both fibrinolytic and coagulation systems. Among the 
proteins plasminogen is said to have striking homology to apo(a) due to 
similarities of several features between the two compounds. Inspite of the 
homology, apo(a) does not possess the proteolytic activity of the active form of 
plasminogen namely plasmin which results in fibrinolysis since the preactivation 
peptide and the kringles I-III present in the latter are absent in apo(a)(50). Similarly 
while the active site of plasminogen present in the protease domain is formed by 
Arg-Val that in apo(a) has Ser-Val. 
 The difference with the active site of the two components is said to result 
in the abscence of any cleavage of apo(a) to a form which will have proteolytic 
activity similar to plasmin. However in 1992 an alternative site for proteolytic 
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action for apo(a) has been suggested by Guerva et al.,(17) thereby suggesting a 
protease activity to apo(a) different from that of plasmin. 
ISOFORMS OF Apo(a) 
 In 1987, 6 isoforms of  apo(a)  of  different  masses  ranging  from 400-
800kDa were demonstrated by Uttermann and coworkers(19,51). When compared to 
apoB100 the relative mobilities of apo(a) categorized into 3 types of isoforms 
based on electrophoretic mobility in comparison to apoB100 which are faster than 
apoB100, similar to apoB100 and 4 types slower than apoB100 which are S1, S2, 
S3, S4 were recognized. The (Chart No.2) also gives the number of KIV repeats, 
molecular weight, size and the concentration of the isoforms in the blood. 
GENETIC BACKGROUND OF Apo(a) AND Lp(a) 
 While Lp(a) is said to be inherited as an Autosomal Dominant trait, apo(a) 
is considered to be a superfamily of Trypsin like serine protease which consists of 
4-proteases namely apo(a), plasminogen and hepatocyte growth factor I and II(18). 
 The ability to synthesize apo(a) is confined to a restricted group of 
primates; however, the insectivore hedgehog produces an apo(a) like protein 
composed of multiple tandem repeats of a plasminogen kringle III homologous 
domain but lacking the protease domain(52). 
 The human apo(a) gene is located in a gene cluster within 400kb of 
genomic DNA on the telomeric region of chromosome 6(6q 26-27)(53,54) including 
the sequence encoding apo(a), plasminogen and other two pseudogenes with 
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highly homologous untranslated 5l flanking regions(55). Three additional 
homologous genes designated as plasminogen - related genes have been identified 
unlinked to the apo(a) gene cluster and resident on chromosome 2 and 4. 
 The apo(a) gene belongs to a puzzling gene family that includes several 
similar sequences encoding prothrombin, tissue - type plasminogen activator (t-
PA), urokinase A - chain, plasminogen, coagulation factor XII, Macrophage 
stimulating factor, hepatocyte growth factor and other unclear function(56). 
Nucleotide analysis of human genes encoding these proteins reveals that 
sequences of exon  and  relative  boundaries  differ  only  from 1 to 5% and that 
the types of exon / intron functions and the positions of introns in the sequences 
are almost identical. These data suggest that the genes might have developed 
during recent primate evolution from a common ancestral component of the 
kringle - related serine proteases, most likely plasminogen via duplication and 
exon shuffling(52). 
 The apo(a) gene shares the highest homologies with the gene of the 
zymogen plasminogen. The sequence encoding for plasminogen kringle V 
domain is retained, whereas the plasminogen kringle IV domain encoding 
sequence, exists in multiple variable tandem repeats. In contrast, apo(a) lacks the 
sequences of plasminogen preactive region and plasminogen kringle domains I 
through III despite the strong genetic homologies, a single point mutation in the 
sequence of the protease domain deprives apo(a) of most of plasminogens 
enzymatic properties.  
 Apo(a) and plasminogen genes are about 50 kb apart and are oriented in 
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opposite directions. The leader sequence of apo(a) is separated from the first 
kringle of apo(a) by an ~14kB intron. In the variable apo(a) KIV repeat domain 
the coding region for one KIV is split into 2 exons of 162bp (EXON-1) and 
180bp (EXON-2) by the 4.2 kb intron 1. Between the 3l end of 2nd exon and 5l 
end of next exon is a 1.4 kb intron 2. There are multiple copies of Exon 1 and 
Exon 2 encoding KIV repeats. The total size of genomic KIV repeats is 5.6 kb. 
The high degree of internal KIV repeats in "Complementary DNA" of apo(a) 
suggests that the size polymorphism of the protein may be due to inherited 
differences in the number of KIV repeats in the gene. The high quantitative 
polymorphism in the sequence encoding the plasminogen KIV Type 2 domain 
explains the high degree of individual allelic size polymorphism of the protein, as 
to date no fewer than 34 size allele have been identified in the apo(a) locus, 
encoding as many detectable isoforms in plasma(52,59). The autosomal codominant 
inheritance of apo(a) isoforms are said to be controlled by a series of a autosomal 
alleles LpF, LpB, LpS1, LpS2, LpS3, LpS4 at a single locus. A seventh allele Lp0 (null 
allele) has been found to control the null type isoform where there is no detectable 
isoforms(19). 
 The size of apo(a) particle usually determines its rate of hepatic synthesis 
and secretion; Null alleles, producing virtually no detectable circulating Lp(a), can 
be frequently observed. The molecular basis of these null allele seems to be an 
inframe 47 amino acid delection in the sequence of the protease domain that 
hinders the correct splicing of mRNA and generates a defective protein, 
irregularly subjected to a sequence of intracellular rearrangements which are 
essential for processing and secretion of complete and functional particles(60).  
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Among  these,  the  trimming  of  N-linked glucoses which occurs after the 
folding of the protein into the endoplasmic reticulum, is thought to be a critical 
process(61). 
SYNTHESIS OF Apo(a) AND Lp(a) 
 Various studies have shown that apo(a) is formed as a precursor with a 
molecular weight more than the mature secreted protein. Most intracellular apo(a) 
as per the study of Gerd Utermann exists as a precursor of ~400kDa in the 
endoplasmic reticulum and is free unassembled with apoB100 : but the mature 
intracellular form of apo(a) exists as  700kDa  form  in  Golgi  fraction and  is  
assembled  with  apoB100(19). As  per  the  study  of  Rath M Niedorf A et al.,(62). 
Lp(a) is produced in the endoplasmic reticulum of liver where it is presumably 
linked to apoB100. In the endoplasmic reticulum and later in the Golgi apparatus 
apoB100 is loaded with triglyceride for secretion as very low density lipoprotein. 
Although the density of most Lp(a) falls between the densities of low and high 
density lipoprotein, Lp(a) can circulate with triglyceride rich lipoproteins and is 
presumably secreted as such(63,64). 
 Apo(a) mRNA is said to be present in liver, testes, brain but is most 
abundant in liver(17,19). Among the organs, liver alone produces apoB100. Hence 
the potential to assemble apo(a) into Lp(a) is said to be present only in liver(65). 
 Though the above data give the idea that Lp(a) is formed within the liver 
cell alone, extracellular assembly is said to be certainly possible. Various studies 
done with transgenic mice and humans have shown that Lp(a) is also formed in 
plasma by the association of LDL with apo(a) secreted into plasma in the free 
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form. Apo(a) in Lp(a) is believed to be derived from a pool that is metabolically 
different from the pool from which LDL is found. 
FUNCTIONS OF Lp(a) 
 Various functions have been attributed to Lp(a) which are enumerated 
below : 
 I. Tissue Repair 
 II. Inhibition of fibrinolysis 
 III. Effect on Atherogenesis 
 IV. Inhibition of cancer growth and spread 
 V. Acts as a surrogate for ascorbate  
 I. Tissue Repair 
 It now seems likely that Lp(a) offered an evolutionary advantage to 
humans by promoting and accelerating the healing of wounds and the repair of 
tissue injuries and vascular lesions. 
 Lp(a) behaves as an acute phase reactant. The sequence of the apo(a) gene 
contains interleukin - 6 (IL-6) responsive elements that enhance transcription of 
the gene(150). IL-6 generates a marked, dose dependent enhancement of apo(a) 
mRNA sysnthesis that leads to the accumulation of Lp(a) particles in hepatocyte 
culture(151(. 
 Due to the additional presence of apo(a), Lp(a) can be recognized by a 
broad variety of receptors at the surface of endothelial cells, macrophages, 
fibroblasts and plateletes(152,153). Defensin, a peptide, released from activated or 
  
 12
senescent neutrophils, enhance the binding of Lp(a) to endothelial cells by 
approximately four fold and to smooth muscle cells by six fold(154). Although it is 
not yet clear whether Lp(a) particles are internalised directly or instead by prior, 
extracellular degradation, the large amount of cholesterol carried by the 
lipoprotein can easily be extracted and used at the site of its accumulation. 
 Lp(a) binds to several compartments of the vascular wall and the 
subendothelial matrix(155); this binding is partially mediated by the lysine binding 
sites (LBS) of its apo(a) moiety(153). High affinity bindings to fibronectin, 
fibrinogen, glycosaminoglycans and proteoglycans were observed in the presence 
of Ca2+ and Mg2+ ions; further weaker interactions were described with laminin 
and beta - 2 glycoprotein I, but no binding was observed to von wille brand factor, 
vitronectin or collagen Type IV(155,156,157). 
 Accumulation of Lp(a) molecules has been demonstrated in the arterial 
walls of human coronary and cerebral vessels(158), aorta and peripheral arteries. In 
those sites, the relative amount of apo(a) deposition is significantly related to the 
extent of atherosclerosis. Large amounts of Lp(a) can be demonstrated in growing 
atherosclerotic plaque and vein grafts(159). In growing atherosclerotic lesions the 
accumulation of apo(a) in degraded, free and intact (but oxidized) forms appear to 
be preferential to that of other apolipoprotein(160). This process might be attributed 
to the tendency of apo(a), to bind to connective tissue elements such as 
proteoglycans, glycosaminoglycans and especially fibronectin(155). 
 The cellular uptake and degradation of Lp(a) follows several pathways as 
Lp(a) particles bind to a wide variety of cellular receptors(161,162,163,164,165,166) and 
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other unrecognized endosomal membrane proteins(163). This binding process is 
promoted by lipoprotein lipase or sphingomyelinase(167). Lipoprotein lipase 
enhances the cell association of Lp(a) five fold and the consequent cellular 
degradation by about three fold(168) whereas the oxidative modification of Lp(a) 
results in avid uptake by monocyte - macrophages(169). The affinity of Lp(a) to 
triglyceride rich lipoproteins and LDL's and the strong molecular interactions with 
several components of the endothelial matrix might further enhance the 
catabolism of Lp(a) by alternative as yet unclear pathways, promoting accelerated 
internalisation and degradation of cholesterol rich lipoproteins(170). Lp(a) particles 
are susceptible to oxidative modification and scavenger receptor uptake, leading 
to intracellular cholesterol accumulation and foam cell formation(171,172) which 
contributes further to atherogenesis. The raised sialic content of Lp(a) is thought 
to contribute to the oxidative resistance of the native particle(172). Finally increased 
Lp(a) levels are associated with a selective impairment of vasodilator capacity of 
receptor mediated endothelial stimuli, contributing to the pathogenesis of 
myocardial ischaemia(173). 
II. Inhibition of Fibrinolysis 
 Lp(a) displays unequivocal growth factor like properties promoting growth 
of human umbilical vein endothelial cells (hUVECs) in synergy with basic 
fibroblast growth factor and insulin(174) and enhancing the proliferation of human 
vascular smooth muscle cells (hVSMCs) in culture by inhibiting the activation of 
transforming growth factor. These observation are not surprising in view of the 
fact that apo(a) belongs to a family of growth factors evolved from a common 
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ancestral kringle containing serine protease, including the hepatocyte growth 
factor / scatter factor (HGF/SF) a potent effector in promoting growth, movement 
and differentiation of epithelial,  endothelial and the hepatocytic growth factor / 
macrophage stimulating protein (HGF1/MSP) an effector of macrophage 
chemotaxis and phagocytosis(175).  Role  of  Lp(a)  in  Tissue  Repair  is 
summarized in (Chart No.3). 
 As a vascular injury occurs, the acute phase response, concomitantly 
induced by the cellular release of several mediators including IL-6 stimulates the 
hepatic synthesis of newly formed apo(a) particles in the blood steam. Shortly 
afterwards apo(a) accumulates at the site of vascular injury as it binds to cellular 
receptors present in the surface of residual vascular cells, macrophages and 
platelets and also to the exposed subendothelial matrix and to immobilized fibrin. 
The large amount of apo(a) bound to the fibrin surface and endothelial cells, 
inhibits the lysis of clot. 
 The role of Lp(a) in inhibition of fibrinolysis is illustrated in Chart No.5. 
Though the extensive homology of apo(a) with plasminogen has raised the 
possibility that apo(a) may function similar to the former protein in the fibrinolytic 
process, it has been found that it is not so. Infact the reality is that apo(a) present 
in Lp(a) interferes with many steps in the complex biochemical cascade of 
reactions involved in fibrinolysis as illustrated in Chart No.5; the reactions leading 
to fibrinolysis are depicted in Chart No.4. 
1. As illustrated in the charts Lp(a) inhibits fibrinolysis by competing 
with plasminogen in the following manner(19,178,179,180): 
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 a. Competition for plasminogen activation by tissue plasminogen 
activator (t-PA). 
 t-PA synthesized and released from endothelial cells, binds at a separate 
domain of Annexin II (multi domain amphipathic phospholipids binding protein 
and a unique endothelial membrane site for fibrinolytic assembly systems). The 
above multimolecular complex leads to a cell bound plasmin that contributes to 
the nonthrombogenic character of the endothelial cell surface. By interfering with 
this assembly via direct competition with plasminogen binding, Lp(a) 
downregulates endothelial cell plasmin generation and shifts the vessel surface to 
a more thrombogenic phenotype(17,18). In addition Lp(a) also acts as a competitive 
inhibitor of t-PA in the presence of fibrinogen(17,19). 
 b. Competition for plasminogen binding to fibrinogen and fibrin. 
 Lp(a) may bind to fibrin via kringles in apo(a), thus delivering cholesterol 
to sites of recent injury and wound healing(17,181). This binding of plasminogen to 
fibrin is normally mediated by lysine (fibrin) binding site of plasminogen KI. This 
binding is enhanced by plasminogen activators. Plasmin formed by activation 
induces modification in fibrin that in turn creates more plasminogen binding. 
Lp(a) competes with this binding site and inhibits the binding of plasminogen to 
fibrinogen and fibrin thus inhibiting fibrinolysis and promoting thrombosis. 
 c. Competition for plasminogen binding to cellular binding sites. 
 The fibrinolytic system in contact with the surface of endothelial cells play 
a critical role in thromboregulation. Glucose - plasminogen is the main circulating 
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fibrinolytic zymogen which binds specifically to plasminogen receptors at the 
endothelial cell surface thereby triggering an increase of several folds in plasmin 
generation by t-PA (by conversion of Glucose - Plasminogen to Lysine - 
Plasminogen). Lp(a) inhibits Glucose - Plasminogen binding to the endothelial 
cell receptors(17,19). 
 d. Competition for Plasminogen (PMN) binding to tetranectin 
 Tetranectin is a plasma protein which binds reversibly to KIV of 
plasminogen (PMN) and enhances plasminogen activation by t-PA. Lp(a) binds to 
tetranectin with high affinity whereby less plasmin is formed resulting in 
decreased fibrinolysis(17,19). 
 e. Enhancement of plasminogen activator inhibitor (PAI-1) 
activity  
 Lp(a) regulates expression of PAI-1. It increases the amount of PA1-1 
activity(17,18,19). All the above functions of Lp(a) are said to contribute to the 
proatherogenic property of Lp(a). 
 2. Lp(a) has also been found to aid in the formation of fibrin network 
where the proteins fibrin, fibronectin, fibrinogen and apo(a) are held as a mesh by 
cross linking between Endo γ glutamyl and Endo-ε-lysyl residues of the above 
protein(19). The crosslinking of the above (protein) surface structures aid in the 
deposition of Lp(a) in the growing atherosclerotic plaques. 
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 Hence from the inhibitory functions of Lp(a) on plasminogen it is clear 
that Lp(a) interferes with fibrinolysis but aid clot formation whereby the delicate 
balance between the complex cascade of reactions between clot formation and 
degradation is tilted towards the former. 
III. Atherogenic effects of Lp(a) 
 The various modes by which Lp(a) contributes towards atherogenesis is 
given below and also illustrated and in Chart No.6. 
a. Lp(a) has the capacity to bind to glycosaminoglycans; it is all the more 
trapped in atherosclerotic plaques, thus contributing to atherogenesis. 
b. Lp(a) forms complexes with proteoglycans and are taken up by 
macrophages. Lp(a) which is converted to oxidized Lp(a) by 
polymorphonuclear leucocytes are also taken up by macrophages via 
scavenger receptors. Both lead to foam cell formation and cytokine 
production which acts as a chemoattractant and mitogen for smooth muscle 
cells. 
c. Lp(a) interacts with platelets interfering with platelet aggregation. 
d. Lp(a) by downregulating the generation of plasmin which normally 
activates transforming growth factors β (TGF-β) and thereby blocks 
smooth muscle proliferation is able to impair activation of TGF-β thereby 
contribute to smooth muscle cell proliferation. 
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e. Lp(a) is also said to decrease production of endothelial derived growth 
factor (EDGF) and increase production of adhesive glycoprotein 
intercellular adhesion molecule - I (ICAM-1). 
 Hence it is clear that apo(a) aid atherosclerosis not only by interfering with 
fibrinolysis and promoting a mesh of it with fibrin but also by its other functions 
which affect smooth muscles and EDGF. This is illustrated in Chart No.6. 
 In a nutshell it is said that the atherogenic effect of Lp(a) is due to the 
cholesterol delivery to the site of injury or to the endothelial cells, blocking of 
plasmin generation, endothelial cell modulation, smooth muscle cell proliferation 
and angiogenesis(18). Lp(a) is said to cause neovascularization atherosclerotic 
plaque thus contributing to angiogenesis(18). Marlys L Kochinsky, Ph.D., has 
identified the association of Lp(a) with atherothrombotic disease and has also 
further classified the potential mechanism by which Lp(a) increase leads to the 
atherosclerosis as proatherogenic and prothrombotic(192). The same has been 
illustrated in Chart No.7. 
IV. Lp(a) inhibits cancer growth and spread 
 Angiostat, a38kDa fragment generated by cancer mediated proteolysis of a 
plasminogen including plasminogen kringle domains I through IV inhibits 
neovascularisation of tumors and metastasis(184, 185). Furthermore, recombinant 
form of plasminogen i.e. kringle V domain sharing high sequence homology with 
four kringles of angiostatin inhibits endothelial cell migration(186). 
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 As most plasminogen derived kringles have strong inhibitory effect on 
angiogenesis(185,186) and as the polar kringle domains are highly homologous to 
plasminogen residues (77-100%)(187) it is quite conceivable that Lp(a) kringle 
fragments produced after physiological degradation of whole particles in vivo(188) 
have similar properties in anatoganizing or reducing growth and spread of cancer. 
The concentration of Lp(a) is commonly reported to be significantly increased in 
cancer patients as compared to health controls, irrespective of source and degree 
of the malignancy tumor(189). However the clinical relationship between Lp(a) and 
cancer is still obscure.  
V. Lp(a) is a surrogate for Ascorbate 
 According to the classic "Unified theory" of former Nobel prize winner 
Linus C Pauling and Mathias Rath, Human occlusive cardiovascular disease is a 
degenerative condition induced by chronic Ascorbate deficiency in which the 
large extracellular deposition of Lp(a) represents a powerful biological defence 
mechanism(190,191). Thereby Lp(a) is regarded as surrogate for Ascorbate. No other 
reliable or biological evidence regarding the above topic has been published after 
the studies of Rath and Pauling. 
SERUM LEVELS OF Lp(a) 
 Lp(a) is fully expressed in the first year life(70,71). Plasma concentration is 
said to be heritable through kringle isoform transmission and is constant relatively 
throughout life(72). It is said that due to the fact that both male and female sex 
hormones suppress Lp(a) there is lack of sex difference noted for the lipoprotein. 
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However Jacques Genest Jr et al.,(91) has given different reference range for males 
and females. Plasma Lp(a) concentration is said to vary from undetectable levels 
to 1 gm/dl(86). There is strong evidence that Lp(a) levels are more dependent on 
synthesis of apo(a) than its catabolic rate. The distribution of Lp(a) in the 
population was highly skewed by Harlampos J Milionis et al., among 
population(123). Approximately 90% of the population in England had serum levels 
less than 30mg/dl  and occasionally patients had above 20,000 mg/dl(68). As per 
Srinivasan SR et al.,(69) blacks had several fold higher Lp(a) than Asian and 
Caucasians. The pathological effects due to increased Lp(a) was noticed when it 
exceeded 30 mg/dl(87,88,72,89,69,90). 
 Reference plasma concentration of Lp(a) as determined by several workers 
in the field are given below. 
1. James A Hearn et al.,(92)  : Less than 4mg/dl 
2. Jacques Genest Jr et al.,(91) : Male 13 - 14 mg/dl 
        Female 14- 16 mg/dl 
3. Berg et al.,    : 15-20 mg/dl 
4. Harlampos J Milionis(123)  : Less than 30 mg/dl 
5. Bernard Cantin et al., : 32-34 mg/dl 
6. Devanapalli(193)   : 32.5 mg/dl for Asian Indians 
 Sex hormones and related compounds estrogen(73,74), progestin(75,76), 
estrogen - progestin combination(77), testosterone(78), anabolic steroids(78,76), 
tamoxifen(80), raloxifene(81) and corticotrophin and dexamethasone(82) have been 
found to lower Lp(a). Growth hormones have been shown to increase Lp(a). 
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Exercise, environmental factors, age and body mass index have been found to 
have little effect on Lp(a)(40,47,83,84,85). But PB Duell et al.,(194) have found Lp(a) can 
be modulated by a complex interplay between insulin action, obesity, androgen 
levels and strenuous exercise(194). 
 Diets low in saturated fat and cholesterol had no effect on Lp(a) 
concentration(127) and studies of increased or decreased intakes of cholesterol and 
saturated and polyunsaturated n-6 and n-3 fatty acids similarly showed no or 
marginal effects on Lp(a)(128,129). 
 Certian dietary fatty acids may however affect Lp(a) concentration. 
Transmonounsaturated fatty acids constituting 5 to 10% of total energy intake 
increased Lp(a) by 20 - 70%(130,131) whereas transmonounsaturated fatty acids 
contributing 4% of energy intake and insignificant effects(132). 
 Fish-oil lowers Lp(a) concentration by 15% in normolipemic individuals 
Lp(a) concentration less than 200mg/dl(133) and by 37% hypertriglyceridemia 
patients(134) as it is said to decrease secretion of VLDL. 
 Plasma Lp(a) concentration were 25 - 33% lower when the subjects 
consumed a diet containing either palmitic acid or myristic acid + lauric acid then 
when they consumed a diet containing stearic acid(135). 
 Of the dietary proteins, plant proteins (particularly soy protein) have been 
found to lower atherogenic lipoproteins and sometimes increase antiatherogenic 
HDL as well. 
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 Heavy alcohol consumption is said to lower Lp(a) and withdrawal causes 
rapid increase in Lp(a). 
 Of the hypolipemic drugs only neomycin sulphate(19,46,136,51,137,21) and 
nicotinic acid(138,139) decreased Lp(a) concentration substantially. Statins and bile 
acid sequestrants either had no effect or increased Lp(a)(144,145). Fibrates appeared 
to lower Lp(a) to a modest degree(146,147). 
CLINICAL SIGNIFICANCE 
 Lp(a) is an acute phase reactant(93,94). Hence it is found to be increased in 
patients with cardiopulmonary bypass(17,48), on patients developing restenosis after 
PTCA, cerebrovascular disease(95,96,97,98), coronary atherosclerosis in cardiac 
transplant recipients(99), saphenous vein graft stenosis following bypass and 
peripheral arterial disease (PAD). 
 Lp(a) values can be increased as a part of cancer(100), menopause, 
hypothyroidism(101). Lp(a) values can be decreased in liver failure(102) and 
hyperthyroidism(103). Lp(a) when correlated with renal disease it is found to be 
increased in patients with Nephrotic Syndrome(104,105), (ESRD) end stage renal 
disease(106,107), in patients following renal transplantation in ESRD(108,109,110,111,112). 
Increased serum Lp(a) is seen in both Type 1 and Type 2 Diabetic 
Patients(23,113,114,115). 
CATABOLISM OF Lp(a) 
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 This is said to take place mainly by 3 events(46). They are :- 
 1. Oxidative events  2. Proteolytic events  3. Lipolytic events. 
 In addition to the above 3 events reductive processes have also been found 
to play a part in the catabolism of Lp(a). All the 4 processes of catabolism of 
Lp(a) have been illustrated in Chart No.8. 
1. Oxidative Events 
 Catabolism of Lp(a) is found to be similar to that of LDL. Lp(a) is 
oxidized by polymorphonuclear leucocytes and oxidized Lp(a) is taken up by the 
scavenger receptor of macrophages. The binding of Lp(a) to the above receptors 
and also to cell surface receptors of smooth muscle cells, lymphocytes and 
endothelial cells seem to play a role in the regulation of intracellular cholesterol 
metabolism and also in the removal of Lp(a) from plasma. Though Lp(a) and 
LDL are assumed to bind to some type of receptors, there are said to be 
differences in affinity and binding capacity of the larger molecular weight of 
Lp(a)(45). Suggestion of two different conformations of receptor - protein, one for 
Lp(a) and one for LDL are also available(45). More details of the same however are 
yet to be known. 
 Though the above details have given an ideal that Lp(a) under normal 
conditions is bound to receptors and degraded by receptor system, the exact 
percentage of Lp(a) pool cleared by receptor pathway is yet to be known. 
PROTEOLYTIC EVENTS 
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 Pancreatic and leucocytic elastases and cleaves apo(a) to generate 2 
fragments F1 and F2 which represents the N-terminal and C-terminal domain of 
apo(a) respectively. As F2 remains bound to apoB100 of LDL by the disulphide 
linkage it is said to form a mini Lp(a) particle which  is  also  depicted  in  Figure 
No.6. 
 F1 Fragment has been reported in plasma and urine in normal conditions 
and has been found to be increased in some pathological conditions. 
LIPOLYTIC EVENTS 
 Enzymes like secretory phospholipase A2 and sphingomyelinase which are 
active in the arterial wall are said to act on Lp(a). 
 They are said to modify Lp(a) as well as LDL due to which the 2 
molecules bind more readily to proteoglycans, lysine etc. The above effect of the 
enzyme on Lp(a) is said to be due to the exposure of a 2nd lysine binding site on 
apo(a). 
DIABETES MELLITUS 
 DEFINITION 
 Diabetes mellitus is characterized by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion, insulin action or both. When fully expressed diabetes is 
characterized by fasting hyperglycaemia, but the disease can also be recognized 
during less overt stages, most usually by the presence of glucose intolerance, most 
usually by the presence of glucose intolerance. The effect of diabetes mellitus 
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include long term damage, dysfunction and failure of various organs, especially 
the eyes, kidneys, heart and blood vessels. Diabetes may present with 
characteristic symptom such as thirst, polyuria, blurring of vision, weight loss and 
polyphagia and in its most severe forms, with ketoacidosis or non ketotic 
hyperosmolarity, which in the absence of effective treatment, leads to stupor, 
coma and death. Often symptoms are not severe or may even be absent. 
 The WHO criteria for the diagnosis of Diabetes is given below : 
 1. Classic symptoms and casual plasma glucose >200mg/dl. 
 2. Fasting plasma glucose > 126mg/dl 
 3. 2 hour post load plasma glucose > 200mg/dl during OGTT. 
 WHO has suggested that in a symptomatic patient a random plasma 
glucose value of 11.1 mmol/l (200mg/dl) or more is diagnostic. 
 This is also adequate for the asymptomatic patient if found on more than 
one occasion (and not due to an obvious hyperglycaemic stimulus such as glucose 
infusion in a surgical patient). If random glucose estimates show lower degrees of 
hyperglycaemia estimation of fasting glucose levels or an oral glucose test may be 
used. 
 Differences between plasma and whole blood glucose concentration and 
between capillary and venous levels are too often ignored. Whole blood values are 
about 10 to 15 percent lower than those of plasma and capillary values are 7 
percent higher than venous values in the fasting state and 8 percent higher after a 
glucose load. (It should also be noted that many patients who fall within the lower 
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part of the diabetic range (as defined the WHO) are also only Chemical Diabetics 
in the sense that they have no symptoms and no evidence of diabetic tissue 
damage on examination). 
ETIOLOGIC TYPES 
 The etiologic classification of diabetes mellitus currently recommended by 
WHO and ADA is presented in (Chart No.9). This classification  differs  
considerably  from  the  previously  recommended classification,  which  used  the 
 terms  insulin dependent  diabetes  and  non-insulin dependent diabetes(195). These 
terms, however, were frequently misused and at best classified patients based on 
treatment needs rather than on etiologic characteristics. The most common forms 
of diabetes mellitus named as Type 1 and Type 2 have been reviewed below. 
TYPE 1 : DIABETES MELLITUS 
 Type 1 diabetes is the form of the disease due primarily to β - cell 
destruction. This usually leads to a type of diabetes in which insulin is required for 
survival. Individuals with type 1 diabetes are metabolically normal before the 
disease is clinically manifest, but the process of β-cell destruction can be detected 
earlier by the presence of certain autoantibodies. Type 1 diabetes usually is 
characterised  by  the  presence  of  anti-GAD, anti-islet cell or anti insulin 
antibodies, which reflects the autoimmune process that have led to β-cell 
destruction. Individuals who have one of more of these antibodies can be 
subclassified as having type 1A, immune - mediated type 1 diabetes(196,197). 
 Particularly in nonwhites, type 1 diabetes can occur in the absence of 
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autoimmune antibodies and without evidence of any autoimmune disorder. In this 
form of type 1 diabetes, the natural history also is one of progressive disease with 
marked hyperglycaemia resulting in an insulin requirement for prevention of 
ketosis and survival. Such individuals are classified as having type 1B or 
idiopathic diabetes(198). 
 Type 1A diabetes show strong associations with specific haplotypes or  
alleles  at  the DQA - A  and  DQ - B loci of the human leukocyte antigen (HLA) 
complex(199). The rate of β-cell destruction is quite variable, being rapid in some 
individuals, especially in infants and children, slower in adults. Some have modest 
fasting hyperglycaemia that can change rapidly to severe hyperglycaemia or 
ketoacidosis, and others, particularly adults, may retain some residual β-cell 
function for many years and have sometimes been termed as having "latent 
autoimmune diabetes"(200,201). 
 Individuals with type 1 diabetes have low undetectable levels of insulin 
and plasma C-peptide. Patients with type 1A diabetes are also more likely to have 
other concomitant autoimmune disorders, such as Graves disease, Hashimoto 
thyroiditis, Addison disease, vitiligo or pernicious anaemia. 
TYPE 2 : DIABETES MELLITUS 
 Type 2 diabetes is the most common form of diabetes. It is characterized 
by disorders of insulin action and insulin secretion, either of which may be the 
prominent features. 
 Although the specific etiology of this form of diabetes is not known, 
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autoimmune destruction of  the β - cell  does  not  occur. Patients  with  Type 2 
diabetes usually - have insulin resistance and relative, rather than absolute 
deficiency. 
 This form of diabetes is associated with progressive β-cell failure with 
increasing duration of diabetes(202). Ketoacidosis seldom occurs spontaneously but 
can arise with stress associated with another illness such as infection. 
 Most patients with type 2 diabetes are obese when they develop diabetes, 
and obesity aggravates the insulin resistance. Type 2 diabetes frequently goes 
undiagnosed for many years because the hyperglycaemia develops gradually and 
in the earlier stages is not severe enough to produce the classic symptoms of 
diabetes; however, such patients are at increased risk of developing macrovascular 
and microvascular complications. Their circulating insulin levels may be normal 
or elevated yet insufficient to control blood glucose levels within the normal range 
because of their insulin resistance. Thus, they have relative, rather than absolute, 
insulinopaenia. 
 Type 2 diabetes is seen frequently in women who have a previous history 
of gestational diabetes and in individuals with other characteristics of the insulin 
resistance syndrome, such as hypertension or dyslipidemia. The risk of 
developing type 2 diabetes increases with age, obesity and physical inactivity. 
Type 2 diabetes shows strong familial aggregation, so that persons with a parent 
or sibling with the disease are at increased risk, as are individuals with obesity, 
hypertension or dyslipidemia and women with a history of gestational diabetes. 
The frequency of type 2 diabetes varies considerably among different racial or 
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ethnic subgroups. Persons of Native American, Polynesian or Micronesian, Asian 
- Indian, Hispanic or African - American descent are at higher risk than persons of 
European origin(203). Although the disease is most commonly seen in adults, the 
age of onset tends to be earlier in persons of non - European origin. The disease 
can occur at any age and is now seen in children and adolescents(204,205). 
METABOLIC DERANGEMENTS IN DM(206) 
 The derangements in carbohydrate, lipid and protein metabolism in DM 
and the consequent effects of those derangements are illustrated in Chart No.10. 
 Complications of DM 
 They are classified into Acute and Chronic Complication. 
 Acute Complications 
 1. Diabetic ketoacidosis (DKA) 
 2. Hyperosmolar nonketotic coma 
 3. Lactic acidosis 
 Chronic Complications  
 1. Microangiopathy of Retina and kidneys leading to retinopathy, 
Nephropathy respectively. 
 2. Neuropathy 
 3. Macroangiopathy - where there is hyperlipidemia, oxidized LDL 
and Lp(a) all leading to premature atherosclerosis and premature 
ischaemia heart disease. 
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 4. Non enzymatic glycation of proteins. 
INVESTIGATORY PARAMETERS(207) 
 I. BIOCHEMICAL PARAMETERS 
1. Urine Glucose 
 Normally glucose does not appear in urine until plasma glucose is >10 
mmol / L (180 mg/dl). 
2. Blood Glucose  
 Fasting and postprandial blood glucose are more reliable. Postprandial 
blood sugar is useful to diagnose, monitor and screen the disease. When fasting 
blood sugar is greater than 126 mg% or postprandial blood sugar is greater than 
200 mg% and above, disease is well confirmed. But when Fasting blood sugar 
(FBS) is between 110 - 126 mg% or Postprandial blood sugar (PPBS) is between 
126 - 199 mg% the person should be subjected to OGTT. 
3. Glucose Tolerance Test 
 * Oral glucose tolerance test 
 * IV glucose tolerance test 
NORMAL OGTT 
 * Fasting blood glucose 80 - 110 mg% 
 In OGTT 
  a. Peak  is  within  one  hour  and  the level reached is less than 
160 mg/dl 
  b. Level reduces and reaches fasting level by 2 hours. 
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  c. None of the urine samples contain sugar or ketone bodies. 
4. Urine Ketone Bodies (K.B.) 
 * Ace test and ketostix test are used. 
5. Blood Ketones 
 (Acetone, Acetoacetic acid and β hydroxy butyrate). Normally increased 
only when Diabetes mellitus is severe with ketoacidosis. Acutest and ketostix are 
the methods of choice. 
 Normal Reference Range   = < 0.2 mmol / L 
6. Long Term indices of Glycaemic Control 
 a. Glycated Proteins 
 Increased concentrations of glucose in extracellular fluid (ECF) lead to 
nonenzymatic glycation of lysine residues of proteins. This is irreversible and 
until the protein is degraded is this present in glycated form. This concentration 
reflects the mean blood glucose level during the life of that protein. 
 i. Glycated Haemoglobin (HbA1c) 
 It is the condensation of glucose with the N-terminal valine residue of each 
β chain of HbA to form an unstable schiff base. It forms 80% of HbA1. 
 * Reflects the concentration of blood glucose over a period of past 60 
days. 
 * Normal Reference Range (RR) 6 4-6%. More than the RR signifies 
absence of glycaemic control during the past 60 days. 
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 ii. Fructosamine 
 * Formed by interaction of glucose with ε-amino group on lysine 
residues of albumin. 
 * Reflects control over 3 weeks prior to its determination. 
 * Normal reference range 6 205 to 285 mmol/L. 
7. Microalbuminuria 
 * Signal of nearly reversible renal damage. 
 * 24 hours urine albumin estimation is done. 
 * Reference Range - 30 - 300 mg / 24 hours. 
8. Blood Acid Base Status 
 * pH - altered in ketoacidosis. In diabetic ketoacidosis pH is acidic 
and along with pH' Na, K and osmolality is measured. 
9. Blood Lactate Levels 
 * It is increased in Lactic acidosis 
 * Normal reference range 6 5 - 12 mg/dl 
10. Lipid Profile 
 * Total cholesterol increased 
 * TGL is raised (due to increased VLDL) 
 * VLDL is increased 
 * Lp(a) is increased (secondary to nephropathy, impaired TGL 
metabolism, glycosylation impairs its catabolism). 
 * TGL rich lipoprotein remnants increased 
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 * Oxidized LDL and glycated LDL increased. 
II. SERUM INSULIN AND C-PEPTIDE ESSAYS 
III. IMMUNOLOGICAL PARAMETERS 
 i. Antibodies - islet cell antibodies 
  * Insulin Auto antibodies 
  * GAD antibodies 
  * IA-2 antibody (protein tyrosine phosphatase) - denotes that 
the cause is autoimmunity. 
 ii. Genetic Markers 
TREATMENT 
 The treatment which is to be instituted in Diabetes Mellitus from mild to 
severe forms include  
 i. Exercise 
 ii. Diet  
 iii. Drug therapy 
  a. Sulphonyl ureas 
  b. Biguanide 
  c. Thiozolidinediones 
  d. Alpha glycosidase inhibitors 
  e. Meglitinide  
 iv. Insulin 
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Lp(a) IN DIABETES MELLITUS 
 There are several studies that evaluated the relationship between Lp(a) and 
glycaemic control in diabetic patients(9,10). 
 Several people belonging to the medical faculty who have worked with 
Lp(a) have determined that it increases in both types of Diabetes Mellitus. The 
increase was found with Diabetes Mellitus with or without microalbuminuria(116) 
where increased Lp(a) was found to be an independent risk factor for 
atherosclerosis. 
 Different views regarding the influence of glycaemic control on Lp(a) have 
been reviewed which are given below. 
 1. Wester Louis et al.,(208) determined that there was no statistical 
differences between Lp(a) levels of both types of Diabetes mellitus 
and healthy controls. They had proposed that Lp(a) concentration in 
Type 1 and Type 2 Diabetes Mellitus were independent of short 
term and long term glycometabolic control or the occurrence of 
microalbuminiuria, neuropathies or retinopathies. 
 2. CJ Chang et al.,(124) found that Lp(a) levels are not elevated in 
diabetic patients even in poorly controlled metabolic conditions. 
 3. A Perez et al.,(209) have found that in Type 1 diabetes mellitus 
patients, improvement of glycaemic control does not improve 
plasma Lp(a) concentration regardless of baseline Lp(a) levels and 
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the degree of glycaemic control. 
 4. SM Haffner et al.,(122) have arrived at the conclusion that Lp(a) 
levels changed with glycaemic control in Type 1 Diabetes mellitus 
patients. 
 5. JJ Couper et al.,(117) have obtained a rise in Lp(a) levels during 
puberty in Type 1 Diabetes Mellitus. 
 6. Durlach et al., have found that there was no significant difference in 
Lp(a) concentration in Type 2 Diabetes mellitus patients and 
control subjects. 
 7. O'Brien T et al.,(211) have determined that Lp(a) levels were 
significantly higher in Type 2 Diabetes patients than control 
subjects and no association was found between Lp(a) levels and 
glycaemic control or CAD. 
 8. N Waseef et al.,(119) have found significant elevation in both android 
obese and non - obese Type 2 diabetic patients regardless of 
glycaemic control. 
 9. FR Heller et al.,(120) have determined high levels of Lp(a) in insulin 
requiring Type 2 Diabetes mellitus patients and has reasoned out 
chronic hyperinsulinemia as the eventual causal factor. 
 10. WD Scheer et al.,(121) have determined that optimizing body weight 
and tight glycaemic control may beneficially influence Lp(a) values 
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in patients with Type 2 Diabetes mellitus. They also concluded that 
Lp(a) levels was higher in Type 2 diabetes mellitus patients who 
were treated with insulin when compared to those on sulphonyl 
urea therapy. 
 11. T Kikuchi et al.,(212) have said that improvement of glycaemic 
control by insulin therapy does not influence Lp(a) levels in Type 2 
Diabetes mellitus patients independent of baseline values and the 
degree of glycaemic control reached; they have further stated that 
Lp(a) levels are independent of lipid levels in other  lipoporteins  
after  improved  glycaemic  control  in Type 2 diabetes mellitus(213). 
LIPOPROTEIN'S IN DIABETES MELLITUS 
 TYPE 1 DIABETES MELLITUS 
    Very Low Density Lipoproteins 
 Extreme elevations in VLDL have been recognized as being a common 
occurrence in diabetic ketoacidosis, the stage at which insulin concentrations are 
minimal(214). On the other hand, VLDL levels may not be elevated in individuals 
with type 1 diabetes who are receiving adequate therapy. It is now well 
established that elevations in VLDL triglycerides in type 1 diabetes are often 
correlated with the degree of glycaemic control(215,216). 
 In people with untreated type 1 diabetes, the fractional catabolic rate for 
endogenous triglyceride is decreased(217), as is the clearance rate for exogenous 
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triglyceride(218). Thus, when insulin deficiency is extreme, clearance is impaired 
because the activity of LPL is dependent on insulin. In the early stages of insulin 
deficiency, production of VLDL is increased, probably because of the increase in 
mobilization of free fatty acids. This enhanced hepatic secretion of VLDL falls off 
in the later stages of ketoacidosis because of the decrease in hepatic protein 
synthesis secondary to the insulin deficiency. During severe ketoacidosis when 
there is marked insulin deficiency, hypertriglyceridemia is caused primarily by a 
deficiency in LPL acitivty, and overproduction of triglycerides may not occur 
despite elevated levels of free fatty acids. 
LOW DENSITY LIPOPROTEINS 
 LDL concentration appears to vary directly with the extent of 
hyperglycemia. LDL levels are increased in poorly controlled type 1 diabetes 
diabetes. However, in many individuals with type 1 diabetes, LDL concentrations 
are not different from those of age and weight matched controls. 
 In uncontrolled Type 1 diabetes, LDL fractional clearance is probably 
decreased because insulin appears to potentiate LDL binding to its receptor.  
Further, insulin deficiency may lead to overproduction of LDL in response to an 
increased influx of VLDL or its precursor or to impaired removal of VLDL 
remnants by the liver. Abnormalities in the VLDL particle also may influence 
conversion to LDL. 
 Glycated LDL as defects in cholesteryl ester transfer may be found in type 
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1, as well as in type 2, diabetes. 
HIGH DENSITY LIPOPROTEIN 
 In has been suggested that concentrations of HDL may be low in patients 
with untreated insulin - deficient diabetes. Response of HDL to insulin therapy is 
slower than that of VLDL, but HDL increase with the degree of glycaemic 
control. 
 One factor responsible for the decrease in HDL in patients with poorly 
controlled type 1 diabetes is low LPL activity. The reduced activity impairs 
lipolysis of VLDL and subsequently slows formation of HDL particles(219). Levels 
of both HDL cholesterol and phospholipids in type 1 diabetes have been shown to 
correlate positively with LPL activity; thus, greatly increased catabolism of 
triglyceride - rich lipoproteins in the presence of excess insulin might augment the 
HDL compartment. An inverse correlation has been observed between HDL and 
hepatic lipase activity in the plasma of type 1 diabetic subjects. 
TYPE 2 DIABETES MELLITUS 
 Triglycerides and Very Low Density Lipoprotein 
 The most common alteration of lipoprotein in type 2 diabetes is 
hypertriglyceridemia caused by an elevation in VLDL concentrations. In clinical 
descriptions of diabetic hypertriglyceridemia, an emphasis is often placed on 
individuals with extremely high levels of plasma and VLDL triglycerides. It is 
clear, however, from population based studies(220,221) that type 2 diabetes generally 
is associated with only a 50% to 100% elevation in the plasma levels of total and 
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VLDL triglycerides. 
 One of the determinants of diabetic hypertriglyceridemia is the 
overproduction of VLDL triglycerides(222,223,224), which is most likely due to the 
increased flow of subtrates, particularly glucose and free fatty acids, to the liver. 
In addition, individuals with type 2 diabetes appear to have a defect in clearance 
of VLDL triglyceride that parallels the degree of hyperglycaemia(222,223,224,225). 
Studies to date suggest that LPL activity is decreased in individuals with type 2 
diabetes, especially those with moderate to severe hyperglycemia who exhibit 
both insulin deficiency and insulin resistance(226). 
 Patients with type 2 diabetes have a decreased fractional catabolic rate for 
VLDL apo B similar to that for VLDL triglyceride(224). Overproduction of VLDL 
apoB also occurs in type 2 diabetes and it has been suggested that this 
overproduction is further increased by obesity(224). Thus, the extent of 
overproduction of VLDL triglyceride may be greater than that of apoB in type 2 
diabetes, a situation that results in the production of larger triglyceride - rich 
VLDL particles. 
 Hyperinsulinemia and the central obesity that typically accompanies 
insulin resistance also are thought to lead to overproduction and impaired 
catabolism of VLDL. 
 Triglyceride elevation in type 2 diabetes may also be due to delayed 
clearance of postprandial particles(227). Individuals with diabetes, especially those 
with severe hyperglycaemia, may have larger triglyceride rich VLDL(224). This 
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increased ratio of triglyceride to apoB may be a reflection of a disproportionate 
influence of type 2 diabetes on VLDL triglyceride production. Subfractions of 
VLDL have been found to be enriched in the proportion of cholesterol rich 
particles(228). These compositional changes may have implications for the 
increased propensity for atherosclerosis among individuals with type 2 diabetes, 
because cholesterol - enriched VLDL may be atherogenic. Changes in the 
distribution of apoE would have important implications for VLDL metabolism in 
type 2 diabetes because apoE influences the affinity of binding to receptors. 
 apoE  sialation  has  been  reported  to  be  higher  in  diabetic  than  non-
diabetic individuals, a change that may impair binding to the B/E receptor(229). 
Remnant particles from delayed chylomicron clearance may also be present in the 
VLDL fraction; they are subject to the same compositional alterations discussed 
for VLDL. 
LOW DENSITY LIPOPROTEIN 
 The density ranges chosen for quantification, of LDL (1.006 to 1.063) 
result in the inclusion of the IDL fraction. It is possible that the increase in the 
LDL in type 2 diabetes is the result of an increase in this IDL fraction. 
 In individual with type 2 diabetes and relatively severe hyperglycemia, the 
clearance rate for LDL apoB is reduced(224). Mildly hyperglycaemic individuals 
with type 2 diabetes may have increased LDL production as well(230). Because 
LDL binding is stimulated by insulin(231), defect in LDL clearance in type 2 
diabetes may be due to insulin resistance or relative insulin deficiency. This 
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possibility is supported by the observation that clearance of LDL in type 2 
diabetes is positively related to plasma insulin levels and to the insulin response to 
oral glucose challenge. 
 Decreased clearance in type 2 diabetes may lead to increased LDL; on the 
other hand, increased direct removal tends to lower production. These alterations 
in the flux of both VLDL remnants and LDL particles, coupled with the changes 
in LDL composition, indicate the LDL in individuals with type 2 diabetes has 
significant atherogenic potential. 
 An increase in the proportion of small, dense, triglyceride - enriched LDL 
has consistently been observed(228). LDL particles from individuals with diabetes 
have a decreased ability to bind to receptors, and this decrease in binding is 
inversely related to the size and ratio of triglyceride to protein in LDL(232). LDL in 
diabetic individuals has been shown to be more rapidly oxidized. This may be in 
part because of the increased oxidative susceptibility of small, dense LDL 
particles, which are prevalent in diabetic individual also. Oxidized LDL particles 
are believed to play a minor role in stimulating the atherosclerotic process because 
of their recognition by macrophage receptors. 
 Increased plasma triglyceride levels, low HDL levels and small dense 
LDLs usually occur together in a lipoprotein pattern often referred to as 
atherogenic dyslipidemia(233). This abnormal pattern occurs in insulin resistance, is 
exacerbated in diabetes(234), and is derived in part from alterations in apoB 
metabolism because triglyceride rich VLDLs are the precursors of denser LDL 
particles(235). Small dense LDLs are slowly catabolized because they do not bind 
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well to the B/E receptor. 
 Nonenzymatic glycation (or glycosylation) of apoB also may influence 
LDL metabolism in diabetes. Small, dense LDLs are more rapidly glycated. The 
extent of glycation of LDL in individuals with type 2 diabetes who have moderate 
hyperglycaemia is approximately 2% to 5%(236), and this degree of glycation of 
lysine residues has been shown to decrease LDL catabolism in  vivo by 5% to 
25%(237). Glycated LDLs also appear to exhibit altered interactions with 
endothelial cells, stimulate cytokine production, and enhance cholesteryl ester 
synthesis in human macrophages(252). Moreover, glycated LDLs are more readily 
oxidized. Thus, the glycation of LDL may represent an important mechanism by 
which atherogenesis is increased in type 2 diabetes. Together, glycation and 
oxidation render LDLs more immunogenic; the formation of antibody-antigen 
complexes stimulates macrophage accumulation and further foam cell 
formation(238). 
 Finally, a pattern of abnormal cholesterol transport and transfer in the 
plasma has been shown in patients with type 2 diabetes. The transfer of LCAT-
synthesized cholesteryl esters to VLDL and LDL is inhibited, with a concomitant 
increase in their transfer to HDL; this abnormal metabolic pattern is reversed by 
insulin therapy.  The block in cholesterol ester transfer activity in patients with 
type 2 diabetes is correlated with an increase in free cholesterol content of both 
LDL and VLDL. Therefore, in type 2 diabetes, this abnormal cholesteryl ester 
transfer may be related to an increased risk for atherosclerosis. 
HIGH - DENSITY LIPOPROTEIN 
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 Almost as common as the observation of increased VLDL concentrations 
in type 2 diabetes is the finding of decreased concentrations of HDL cholesterol in 
individuals with type 2 diabetes. 
 Individuals with type 2 diabetes have an increased rate of HDL clearance, 
as measured by apoA1 and apoA11 kinetics(239,240). Significant correlation have 
been found between HDL clearance and plasma concentrations of HDL 
cholesterol and apo A1, and the increase in HDL clearance was directly related to 
plasma glucose levels. The finding of increased HDL clearance is consistent with 
lower VLDL clearance and lower LPL activity. Because HDL concentrations, 
especially of larger HDLs, increase during the lipolytic process, the decreases in 
LPL activity and impaired VLDL catabolism have been shown to be correlated 
with decreases in HDL concentrations in patients with type 2 diabetes. Elevated 
hepatic lipase activity also may contribute to the decrease in HDL concentrations 
in type 2 diabetes, because this enzyme also plays a key role in the metabolism of 
HDL. The changes in lipoprotein and hepatic lipases may act in concert to 
decrease HDL levels in type 2 diabetes. 
 Decreased HDL concentrations in type 2 diabetes are reflected mostly in 
decreases in larger particles. As with LDL, in type 2 diabetes an increased 
proportion of triglyceride in HDL has been observed. These compositional 
changes appear to be related to the activity of adipose tissue LPL, because LPL 
deficiency may be a factor responsible for the altered distribution of HDL 
particles in untreated type 2 diabetes(241). Nonenzymatic glycation of HDL appears 
to interfere with HDL receptor binding . Thus, glycation of HDL may also play a 
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role in the lower levels of HDL observed in diabetes. Finally, abnormalities in 
HDL composition have been noted even in individuals with optimal glycaemic 
control(242). All of these alterations in HDL composition may impair the role of 
HDL in reverse cholesterol transport. 
 Changes in HDL metabolism in insulin resistance include  
 a. impaired VLDL lipolysis, which depletes HDL from triglyceride-
rich lipoproteins to the HDL compartment. 
 b. Increased activity of hepatic lipase, which facilitates HDL 
clearance; and  
 c. Alterations in hepatic function, which inhibit production of apoA1 
(the main apoprotein of HDL) and / or hepatic secretion of nascent 
HDL(243). 
 Significant negative relationships between plasma concentrations of insulin 
and HDL have been observed in subjects with type 2 diabetes as well as a 
negative relationship between insulin resistance and HDL cholesterol that is 
independent of insulin or insulin resistance influences the concentration or 
composition of HDL in some way.  
 The influence of type 2 diabetes on Lipoproteins are given in Chart No.11. 
RELATIONSHIP OF Lp(a) WITH LIPOPROTEIN IN DIABETES 
MELLITUS 
 Though much has been reviewed on the effect of glycaemic control on 
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Lp(a) very little information is available on its association with lipoproteins. 
 Cristina Hernandez MD et al.,(244) and few others have observed a positive 
correlation between Lp(a) concentration and LDL cholesterol and an inverse 
independent association between Lp(a) and TGL. Though the same was also 
reported by Rainwater(245) and some others in the non diabetic population(11,12,13,14) 
the influence of LDL cholesterol and triglyceride on Lp(a) was greater in the 
study of the former on diabetic population than in the non diabetic population of 
the latter. This was attributed to the higher frequency of lipid disturbances in the 
diabetic patients as compared to the nondiabetic ones. Cristina Henderson MD et 
al.,(244) who attributed the levels of Lp(a) more to its rate of synthesis that to its 
catabolism attributed the following for correlation between the two. 
 1. Rate of apoB secretion from liver which could be a link between 
Lp(a) and LDL cholesterol. However Morisett et al.,(246) demonstrated apoB in 
LDL is synthesized at a rate approximately four times greater than that of the 
apoB used to produce Lp(a) suggesting that 2 different pools of apo(a) are 
available for lipoprotein metabolism. 
 2. The relationship might be observed because LDL cholesterol 
calculated by the Friedwald formula also contained cholesterol in the Lp(a) 
particle. This fact is emphasized all the more because it has been reported that in 
the general population the correlation of Lp(a) and LDL cholesterol disappeared 
when the contribution of cholesterol of Lp(a) to LDL cholesterol was considered. 
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 AIM OF THE STUDY 
 On having reviewed about Lp(a) and Diabetes Mellitus, the work of 
determining Lp(a) and other associated biochemical parameters namely plasma 
glucose, Total cholesterol, Triglycerides, HDLc, VLDLc and LDLc in the blood 
of healthy and Type 2 diabetics was taken up with the view of establishing the 
following. 
 1. The blood level of Lp(a) in health. 
 2. To determine whether Lp(a) levels differs from that in health and in 
Type 2 Diabetic patients who would be classified into 3 groups ie 
newly diagnosed without treatment and those treated with either 
oral hypoglycemic agents or insulin. 
 3. To find out the relationship between Lp(a) with other biochemical 
parameters in health and the different groups of Type 2 Diabetics 
patients. 
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 MATERIALS AND METHODS 
SUBJECTS 
 The study was carried out on 87 unrelated individuals who have been 
living in Tamilnadu for 3 generation. Out of the 87 subjects 20 were from 
apparently healthy volunteers selected from the staff of MMC or their relatives. 
The remaining 67 were diabetic patients who were selected from the diabetology 
OP of Government General Hospital. 
 Out of 67 diabetic patients selected  based  on  the  selection  criteria' 3 
groups of Type 2 diabetics could be arrived at i.e. 23 of them formed the newly 
diagnosed group while those on treatment were 44 out of which 22 were Type 2 
Diabetics on oral hypoglycemic agents and the other 22 were Type 2 diabetics on 
treatment with insulin. 
 Those individuals who were suffering from diseases like HT, Renal failure, 
liver failure, thyroid dysfunctions, nephrotic syndrome and cardiac pulmonary 
bypass along with alcoholics and smokers were excluded from the study. None of 
the subjects were on any drugs with lipid lowering effect. 
BLOOD COLLECTION 
 7ml of blood was drawn from all the above subjects from the anterior 
cubital vein using sterile disposable syringe. While 1 ml blood was collected into 
a tube containing the anticoagulant - Oxalate and Fluoride (3:1) for blood sugar 
estimation, the remaining was poured into another plain tube for serum separation. 
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The separated serum was centrifuged and from it, 1 ml of clear cell free serum 
was taken and preserved under - 20EC upto 4 weeks for Lp(a) estimation. From 
the remaining serum, analysis of serum lipid profile were performed on the same 
day. 
 The methodology adopted for the analysis of the various parameters is 
given below. 
1. ESTIMATION OF PLASMA GLUCOSE 
 Methodology 
  GOD / POD Method 
 Principle 
     Glucose Oxidase 
 Glucose+O2+H2O  ----------------->  Gluconic Acid+ H2O2 
 
H2O2 + 4 Hydroxy benzoic acid     Peroxidase Quinonemine dye 
 + 4 Aminoantipyrine   -------------->   + 2 H2O 
 The intensity of the pink colour formed is proportional to the glucose 
concentration and can be measured photometrically between 490 to 540 nm. 
 
CALCULATION 
Glucose   = Absorbance of Sample 
__________________   x  
Absorbance of standard 
Concentration of 
standard (mg/dl) 
 Reference Range : 
  Fasting   = 70-110 mg/dl 
 
  Post prandial  = <140 mg/dl 
 
2. SERUM TOTAL CHOLESTEROL 
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 Methodology 
 
  Enzymatic cholesterol oxidase method. 
 
 
 Principle 
 
          Cholesterol esterase 
 Cholesterol ester  + H2O  --------------------->  Cholesterol + 
           fatty acids 
 
          Cholesterol Oxidase 
 Cholesterol ester  + O2  -------------------->  Cholestenone + 
             H2O2 
 
  2H2O2+Phenol+4-   Peroxidase 
 Aminoantipyrine   ----------------->    Red quinone 
             + 4-H2O 
 The concentration of cholesterol in the sample is directly proportional to 
the intensity of the red complex (Red Quinone) which is measured at 500nm. 
 
CALCULATION 
 
Cholesterol 
(mg/dl) = 
Absorbance of test 
__________________      x 200 
Absorbance of standard 
 Linearity upto 500 mg/dl 
 
 
 RR 6 140 to 200 mg/dl 
 
 Range depends on age, sex, diet, race and geographical location. 
3. SERUM TRIGLYCERIDES 
 Methodology 
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  Enzymatic calorimetric method.  
 Principle 
     Lipoprotein  Lipase 
 Triglycerides + H2O -------------------->  Glycerol+Fatty Acid 
     Glycerol Kinase   
 Glycerol + ATP  ----------------->  Glycerol 3 
Phosphate + ADP 
     Glycerol-3-Phosphate  
 Glycerol-3-          Oxidase 
 Phosphate +02  ------------------->  Dihydroxy 
acetone          Phosphate 
+ H2O2 
 2 H2O2+4 Aminoantipyrine Peroxidase    
  +ADPS   ----------------->   Redquinone  
           + 4H2O 
 
 GPO-Glycerol-3-Phosphate Oxidase 
 ADPS = N-Ethyl-N-Sulphopropyl-n-anisidine 
 The intensity of purple coloured complex formed during the reaction is 
directly proportional to the Triglycerides concentration in the sample and is 
measured at 546nm. 
CALCULATION 
         O.D. Sample 
Concentration of Triglycerides (mg/dl) = _______________    x  200 
         O.D.Standard 
 Linearity upto 1000mg / dl 
 
Ref. Range  
 
 Male   - 60 - 145 mg/dl 
 Female - 40 - 140 mg/dl 
4. HDL - CHOLESTEROL 
 METHODOLOGY 
  Phosphotungstic acid method 
 PRINCIPLES 
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  Chylomicrons, LDL and VLDL were precipitated from serum by 
phosphotungstate in the presence of divalent cations such as Mg2+.  After 
centrifugation, the cholesterol in the HDL fraction which remained in the 
supernatant is assayed with enzymatic cholesterol method. 
 
 
CALCULATION 
    O.D. Sample  
HDL Cholesterol =  -------------   x Concentration of 
(mg/dl)   O.D. Standard Std.xDilution Factor 
  
Ref. Range 
  
 In Males  30 - 65 mg / dl 
 In Females   35 - 80 mg / dl 
 
5. VLDL CHOLESTEROL & LDL CHOLESTEROL 
 
 VLDL Cholesterol & LDL Cholesterol were calculated using the 
Friedewald Equation.  
 
 Friedewald Equation 
 
  VLDLc  = TGL / 5 
  LDLc   = Total cholesterol - (HDLc + VLDLc) 
 
 Corrected LDL Cholesterol was obtained from the following formula; 
cholesterol portion of Lp(a), estimated as 0.3 x Lp(a) concentration. 
 
  Corrected LDL = LDL Cholesterol - Cholesterol portion of 
Lp(a)  
 
  Cholesterol portion of Lp(a) =  Lp(a) x 0.3 
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LIPOPROTEIN (a) 
 METHODOLOGY  
  Immunoturbidimetric method 
 PRINCIPLE  
  Latex particles coated with antihuman Lp(a) are agglutinated when 
mixed with samples containing Lp(a). The agglutination causes an absorbance 
change dependent upon the Lp(a) contents of the patient sample, that can be 
interpolated in a calibration curve prepared with different calibrators of different 
Lp(a) contents. 
REAGENT COMPOSITION 
 Lipoprotein (a) R1 
  Buffer solution (pH 8.3)   1x20ml 
 Lipoprotein (a) R2 
  Lipoprotein (a) latex  1x4ml 
 Lipoprotein (a) Calibrator   1x1ml 
LINEARITY 
 The reagent is linear upto 80 mg /dl. Dilute the sample and repeat the 
assay. Multiply the result with dilution factor. 
PREPARATION AND STABILITY OF WORKING REAGENT 
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 Reagent 1 and Reagent 2 are ready to use. It should be mixed gently before 
use. 
CALIBRATOR 
 Reconstitute the calibrator with 1 ml of distilled water and this is stable for 
7 days at 2-8C. 
 Calibration Curve : Prepare dilution of the Lp(a) calibrator using 9g/L 
saline as diluent. 
 
Dilution 1 2 3 4 5 
Calibrator (μ1) 0 25 50 75 100 
Nacl 9g/l (μ1) 100 75 50 25 0 
Dilution Factor 0 0.25 0.5 0.75 1.0 
 
 Multiply the Lp(a) calibrator concentration by the corresponding dilution 
factor indicated in the table to obtain the Lp(a) concentration of the different 
diluted calibrator. 
SAMPLE 
 Fresh serum sample (Free of Hemolysis). 
GENERAL SYSTEM PARAMETER 
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 Mode of reaction  - Fixed time with multi calibrator 
 Slope of reaction  - Increasing 
 Wavelength   - 570 nm  (500 - 600 nm) 
 Temperature   - 37C 
 No. of Calibrators  - 5 
 Calibrator Concentration - as on the vial label X Dilution Factor 
 Linearity   - 80mg/dl 
 Blank    - Deionised water 
 Delay time   - 5 Sec 
 Interval   - 240 Sec 
 Sample Volume  - 15μl 
 Reagent Volume  - 800 μl + 200 μl 
 Cuvette   - 1 cm light path  
LABORATORY PROCEDURE 
 Blank Calibrator Sample 
Calibrator - 15 μl - 
Sample - - 15 μl 
R1 Buffer 800 μl 800 μl 800 μl 
R2 Latex 200 μl 200 μl 200 μl 
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 Mix and read the absorbance against blank after 10 seconds (A1) and after 
4 minute (A2) of the latex addition. 
CALCULATION 
 Calculate the absorbance difference (A2 - A1) of each diluted Lp(a) 
calibrator and plot the values found against the Lp(a) concentration in a 
calibration curve. Lp(a) concentration in the sample is calculated by interpolation 
of the absorbance difference value (A2 - A1) of the sample on the calibration 
curve. 
NORMAL RANGE 
 It is recommended that each laboratory establish its own reference values. 
The following values may be used as guideline. 
 Serum upto 30 mg/dl. 
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 RESULTS 
 The levels of Lp(a) and other biochemical parameters namely plasma 
glucose, Total cholesterol, TGL, HDLc, LDLc and corrected LDLc in the blood 
of all the subjects irrespective of the group to which they belong have been 
indicated in Master Table No.1. The Table No.2 comprises the results of all the 
biochemical parameters in the 20 subjects who were apparently normal healthy 
volunteers. The first 9 subjects of the above table are females while the latter 11 
are males. In Table No.3 the results of all the diabetic patients have been pooled 
together irrespective of the diabetic group to which they belong. Table No.4, 5, 6 
comprise the results from 23 patients of Type 2 Diabetes who were newly 
diagnosed and not on any  treatment,  22 patients from Type 2 diabetes on Oral 
Hypoglycemic agents and 22 patients from Type 2 Diabetes on Insulin therapy 
respectively. In the above tables from 2 to 6 the calculated mean level and the 
standard deviation of each parameter is also given. The above mean level of each 
parameters in the different group is also represented as bar diagrams from 
Fig.No.7 to 9. 
 To find out whether differentiation in sex influences the level of Lp(a) or 
any other biochemical parameter analyzed, the apparently normal healthy males 
and females of Table No.2 were tabled separately in Table No.7 and 8 
respectively. 
 The mean and standard deviation of the parameters in males when 
compared with that of females in Table No.9 revealed statistically that there was 
no appreciable change in the level of any of the parameters with respect to sex. 
Hence irrespective of sex the mean obtained in Table No.2 has been selected for 
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all the biochemical parameters as the Reference range for the study. 
 To find out how far Lp(a) and other parameters varied from the reference 
range in Type 2 Diabetic groups the Mean and Standard deviation of each 
parameter in all the 3 groups of Type 2 Diabetics were compared with that of 
Reference Range in Table No.10, 11, 12 respectively.  
 To determine the difference in the parameters among the Diabetic groups 
analysed intercomparison of the results obtained in the different groups of 
Diabetes was undertaken in Table No.13, 14 and 15. To get at the overall 
perspective of the parameters statistical variation between controls and diabetics, 
the mean and standard deviation of the parameters in the entire group of diabetics 
obtained from Table No.3 have been compared with that of the Reference Range 
in Table No.16.  
 Statistical significance has been derived for each parameter in the 
comparison tables from the p-value obtained which has been calculated using the 
student t-test. 
 To obtain the correlation of Lp(a) with lipid parameters pearsons 
correlation co-efficient were arrived at for each parameter in control and Diabetics 
separately and together for the entire 87 subjects analyzed irrespective of the 
factor whether diabetics or not. The results of pearson's correlation have been 
tabled for  controls  and  diabetics  separately  in  Table No.17 to 23 and for all the 
subjects together in Table No.24. 
 DISCUSSION 
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 To start with, the validity of the reference range (RR) obtained for the 
tested biochemical parameters of serum from Table No.2 which are 77.85 " 13.05 
mg/dl for plasma glucose, 18.69 " 8.87 mg/dl for Lp(a), 181.6 " 24.15 mg/dl for 
Total Cholesterol, 131.10 " 55.65 mg/dl for TGL, 43.35 " 5.04 mg/dl for HDLc, 
26.4 " 11.21 mg/dl for VLDLc, 111.85 " 25.5 mg/dl for LDLc are scrutinized. 
 The mean level of 18.69 " 8.87 mg/dl of Lp(a) obtained from controls is 
well within 15 - 20 mg/dl quoted by Berg et al., and that of Harlampos J Milionis 
et al.,(123) who have given a Reference Range of less than 30 mg/dl. Similarly even 
in the kit methodology adopted for its analysis a level of less than 30 mg/dl has 
been specified as the Reference Range. This level of 18.69 " 8.87 mg/dl of Lp(a) 
is however higher to the Reference Range of 4 mg/dl of James A Hearn(92) and 13 
to 16 mg/dl obtained by Devanapalli et al.,(193) who had worked on Asian Indians. 
 The different levels of reference range of Lp(a) obtained by the various 
workers in the field can be attributed to the fact that plasma Lp(a) level is said to 
be heritable and there is striking difference in its normal levels in various 
population inspite of the fact that Lp(a) in blood is constant at any stage of life(72) 
whether it be newborn, adult or oldage. Moreover it has been reviewed that diet 
can influence Lp(a) levels(247); hence the varied dietary habits of the different races 
of people who had been worked on by the above scientists and the author can also 
be a contributory factor for the different Reference Range of Lp(a) obtained by 
each. 
 The Reference Range obtained for the other routine biochemical 
parameters correlate well to that quoted in standard text books and of course with 
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the Reference Range of kit methodologies selected for evaluating their 
concentrations. Therefore the above mean of each parameter including Lp(a) are 
found to be valid and hence acceptable as Reference Range for the study. 
 Comparison of the mean levels of biochemical parameters of Newly 
diagnosed Type 2 Diabetics who have not been initiated any treatment for it with 
that of controls (Table No.10) shows a S 8 in Lp(a) (p=0.05) and a HS 8 of 
plasma glucose (p = 0.001), TGL (p=0.01) and VLDLc (p=0.01). Similar 
comparison of Type 2 Diabetics on treatment with Oral hypoglycemic agents with 
that of controls (Table No.11) reveals in addition to the statistical significance of 
the former table S 8 of Total Cholesterol (p=0.023), and LDLc (p=0.05) and HS 9 
of HDLc (p=0.001). Comparison of the mean levels in Type 2 Diabetics on 
insulin treatment with that of controls (Table No.12) shows that there is HS 8 of 
Lp(a) (p=0.001) similar to that of plasma glucose (p=0.001), TGL (p=0.009) and 
VLDLc (p=0.01) together with a S 8 of serum Total cholesterol (p=0.024) and 
LDLc (p=0.05) against a S 9 of HDLc (p=0.031). 
 HS increase of plasma glucose in the above 3 Tables is natural as the 
comparison is between diabetics and the non - diabetic healthy. 
 The increase of Lp(a) level in diabetics from its level in healthy controls 
which is obvious in Table No.10, 11, 12 is not a surprise to the author for there are 
several literature evidences that in Diabetes mellitus whether it be in Type 1 or 2 
there is increase of Lp(a). 
 The observed increase of Lp(a) in all 3 groups of diabetics analyzed can be 
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attributed to be due to the following reasons : 
1. As the diabetic groups analyzed belonged to Type 2 Diabetes Mellitus 
where peripheral resistance to the action of insulin is the main causative 
factor, hyperinsulinemia will prevail in the above groups. As it has been 
reviewed that chronic hyperinsulinemia can increase Lp(a) level(120), the 
increase of Lp(a) in Diabetics of our study can be said to be contributed by 
the prevailing hyperinsulinemia. 
2. Increase in the rate of synthesis of Lp(a) as suggested by Cristina 
Hernandez et al.,(244) who have stated that the Lp(a) level is dependent 
more on the rate of its synthesis than on its catabolic rate. 
3. As a link between Lp(a) and LDL through apoB 100 has been established 
by Morrisett et al.,(246) it is inferred that there should be increased rate of 
secretion of apoB 100 from the liver which will contribute towards the 
increase of LDL and Lp(a). 
4. Decreased rate of catabolism of LDL in diabetics(224,231) for which the 
reasons have been already enumerated. As Lp(a) is constituted by apo(a) 
and LDL, decrease in the catabolism of the latter will be naturally reflected 
on the level of Lp(a). 
5. Moreover it has been reviewed that Lp(a) is catabolized by the same 
receptor by which LDL is catabolized. Hence Lp(a) sharing the same 
receptor as LDL for its catabolism will be naturally increased because it 
has been found by Cristina Hernandez et al.,(244) that LDL has a higher 
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affinity for the receptor than Lp(a). Hence when LDL level is increased in 
diabetics it all the more will compete with Lp(a) for the receptor. It has 
also been said that two different conformation of receptor are present for 
binding to Lp(a) and LDL. Therefore it can also be assumed that the 
conformation of the receptor for binding to LDL becomes more prominent 
in conditions where LDL levels increase. This will decrease the catabolism 
of Lp(a) through this route and eventually increase its level in blood. 
Though the exact percentage of Lp(a) catabolized through the receptor 
pathway is not known, the receptor affinity for Lp(a) can be altered in 
Diabetics and thereby lead to an increase of Lp(a). 
 Apt to the statement reviewed in literature, the most common early 
alternation of lipoproteins in Type 2 Diabetes is hypertriglyceridemia resulting 
from evaluation of VLDL concentration, there is a HS 8 of TGL and VLDLc in 
all the 3 groups of Type 2 Diabetes Mellitus from their Reference Range. This 
increase of TGL and VLDLc in Type 2 Diabetes can be due to the following 
facts;  
1. Overproduction of substrates particularly glucose and free fatty acids to 
liver. 
2. Defects in clearance of VLDL triglyceride(224) which is said to parallel the 
degree of hyperglycemia. 
3. Decrease in activity of LPL(226) which normally hydrolyzes triglycerides in 
lipoporteins in VLDL and chylomicrons. 
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4. Overproduction of VLDL apoB and decrease in its fractional catabolic 
rate. 
5. Alteration in the composition of VLDL ie VLDL triglyceride production is 
disproportionately influenced in resulting in large triglyceride rich VLDL 
which have increased ratio of TGL : apoB. As a result of these molecules 
there is increase of VLDL and TGL. 
 The significant increase of LDL cholesterol and Total cholesterol in Type 
2 Diabetics can be the result of the following reasons. 
1. Defect in LDL clearance which may be due to insulin resistance or relative 
insulin deficiency(250). This is said to be due to decrease in LDL binding to 
its receptor which is normally stimulated by insulin. 
2. Reduction in the clearance rate for LDL apoB(250). 
3. Increase in the proportion of small dense triglyceride enriched LDL which 
has decreased ability to bind to receptors(250). 
4. Nonenzymatic glycation of apoB of LDL especially small dense LDL 
which decreases LDL catabolism(250). It is said that glycated LDL's more 
than catabolism are prone for oxidation whereby oxidised LDL is formed. 
5. Block in cholesterol ester transfer activity from HDL to VLDL and LDL 
with an increase in free cholesterol in the latter two(250). 
 On the other hand decrease in HDL cholesterol in Type 2 Diabetes can be 
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attributed to the following reasons. 
1. Increased rate of HDL clearance(250). 
2. Elevated hepatic lipase activity which facilitates its clearance and thereby 
contributes to the decrease of HDL concentration(250). 
3. Decrease in LPL activity and impaired VLDL catabolism decrease the 
concentration of HDL especially larger HDL which normally increase 
during lipolytic process(250). 
4. Alteration in hepatic function which inhibits the production of apoA1 or 
hepatic secretion of nascent HDL(250). 
5. Occurrence of increased proportion of TGL in HDL as a result of the 
activity of adipose tissue LPL, alters the catabolism of HDL(250). 
 Absence of any significant change in Total cholesterol, LDLc or HDLc in 
Newly Diagnosed patients of Type 2 Diabetes which is contrary to the changes 
observed in patients treated with OHA or Insulin can be attributed to the long 
standing duration of the disease in the latter two groups to that of the former 
group. As reviewed, only the earliest lipoprotein change namely increase of TGL 
and VLDLc is seen in the newly diagnosed group of Type 2 Diabetic and hence it 
may be presumed that the subjects belonging to this group have attended the 
Diabetic OP during the early phase of the disease itself. Therefore eventhough the 
plasma glucose level of this group of Type 2 Diabetes Mellitus is higher to the 
other two group of treated Type 2 Diabetes mellitus it has not significantly 
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affected the other lipid parameters. Corrected LDLc does not show any 
significance in the above 3 comparative tables. The absence of any SS for 
corrected LDLc inspite of a S 8 of Lp(a) in Table No.11, 12 suggests that the 
LDLc increase is the result of the additional cholesterol of Lp(a). So when this 
fraction is deducted from LDLc to give the corrected LDL the SS disappears. 
 In comparison of the 3 groups of Diabetics with each other in Table No.13, 
14 and 15 reveals that plasma glucose levels are lower in both the treated groups 
to that in the newly diagnosed groups, the degree of lowering being statistically 
significant. Similarly the levels of HDLc is lower in Type 2 diabetes treated with 
OHA than to its level in the Newly diagnosed group. However statistical 
significance to the extent of HS has been obtained only between the HDLc of the 
Diabetic group on OHA and the Newly diangosed group. Though Barbara V 
Howard and Wm James Howard(248) have stated that improvement in glycaemic 
control elevates HDLc, the glycaemic control achieved by the diabetic patients of 
this study is not sufficient to increase the HDLc level to the level in the Newly 
Diagnosed group which is near normal. 
 The mean level of the assessed parameters of all the 67 diabetic patients 
compared with that of controls (Table No.16) shows a statistical increase in the 
level of all the parameters in diabetics except LDL which is just significant. 
 On analysis of the correlation of Lp(a) with other parameters we find that 
Lp(a) does not correlate to the plasma glucose and that the degree of glycaemic 
control does not influence plasma Lp(a) levels either in controls or any of the 
Diabetic groups analyzed. This finding correlates well to the study of A Perez et 
al.,(209) though his work has been carried out in Type 1 diabetic patients. The 
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absence of any significant correlation between Lp(a) and blood sugar in control 
and diabetics is evident in Table No.17a and 17b. 
 Correlation of Lp(a) with other lipid parameters has revealed a positive HS 
(p=0.001) correlation between Lp(a) and Total cholesterol in Diabetics (Table 
No.18b). This was however absent in controls (Table No.18a) of the study. On the 
other hand TGL (p=0.01) showed a negative correlation with Lp(a) in Diabetics 
(Table No.19b) with absence of any correlation between the two in controls 
(Table No.19a). Among the fractions of cholesterol in the various lipoproteins 
HDLc does not correlate to Lp(a) either in controls or Diabetics (Table No.20a & 
20b); but VLDLc (p=0.015) and LDLc (p=0.001) have negative S correlation and 
positive HS correlation respectively with Lp(a) in the Diabetics (Table No.21b 
and 22b) which is absent in their counter part controls (Table No.21a and 22a). 
Corrected LDL (p=0.001) also has a similar correlation as that of LDLc with 
Lp(a) (Table No.23b). However the correlation of levels of Lp(a) in the entire 87 
subjects irrespective of the fact Diabetic or not proves that only Total cholesterol 
(p=0.001), LDLc (p=0.001) and corrected LDL (p=0.001) have a positive HS 
correlation with Lp(a) (Table No.24). As LDLc is the main lipid fraction of LDL 
and as LDL is a component of Lp(a) the author is not surprised to see the positive 
HS correlation of LDLc or corrected LDLc. Moreover as LDLc is the major 
fraction of the Total cholesterol the HS positive correlation of Lp(a) with LDLc is 
also reflected on Total cholesterol. 
 Since the level of the main biochemical parameters of this study namely 
Lp(a) differs statistically by a HS degree between controls and diabetics attempt is 
made to arrive at a cut off level for this parameter between the two groups. For 
this purpose the levels of Lp(a) in the 20 controls and 18 of each group of Type 2 
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diabetes are plotted as line diagram in Graph No.1. 
 Various cut off levels have been selected from the graph between controls 
and the diabetic and the sensitivity, specificity, positive predictive value and 
negative predictive value have been calculated and shown in Table No.25. From 
this table it is clear that 25 mg/dl of Lp(a) is the most appropriate cut off level to 
demarcate between controls and Type 2 Diabetes. The same has also been 
depicted in Graph No.1. 
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 CONCLUSION 
 From the results on the study on 87 subjects consisting of 20 control, 23 
Type 2 diabetic patients who were newly diagnosed and not on any treatment, 22 
Type 2 diabetic patients on oral hypoglycemic agents and 22 type 2 diabetic 
patients on insulin therapy in whom serum Lp(a) along with plasma glucose, 
serum total cholesterol, serum triglycerides, serum HDLc were analyzed and 
VLDLc, LDLc and corrected LDLc were calculated the following facts are 
revalued. 
 1. Reference range for serum Lp(a) in the study is 18.69 " 8.87. 
Difference in sex does not alter the RR of Lp(a). 
 2. Serum Lp(a) is elevated in Type 2 diabetics. The increase is found 
in Diabetic irrespective of whether newly diagnosed not on 
treatment or old cases on treatment with OHA or insulin. 
 3. Serum Lp(a) does not correlate to plasma glucose i.e to the level of 
glycaemic control. 
 4. Serum Lp(a) does not correlate with any of the lipid parameters in 
controls. 
 5. Serum Lp(a) positively correlates with Total cholesterol, LDLc, and 
corrected LDLc and negatively with TGL and VLDLc in diabetics. 
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 6. The most appropriate cut off level of Lp(a) between controls and 
diabetics is 25 mg/dl. 
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 SCOPE FOR FURTHER STUDY 
 1. Lp(a) assessment can be done during various age groups from birth. 
 2. Lp(a) levels of siblings can be correlated with parents to find out 
the degree of inheritance. 
 3. Lp(a) assessment between premenopausal and post menopausal 
women. 
 4. Lp(a) can be assessed in Type 2 DM with mild glycaemic control, 
moderate glycaemic control, tight glycaemic control. 
 5. To study the association of Lp(a) and the development of Diabetic 
complications. 
 6. To determine the concentration of the different types of LDL in 
diabetes that promote atherosclerosis. 
 7. To find out Lp(a) levels type 1 diabetes patients. 
 8. Lp(a) can be assessed in various grades of coronary heart diseases. 
 9. Lp(a) assessment can be done in relation to other risk factors in 
AMI. 
 10. Lp(a) can be assessed from the time of onset of AMI through the 
course of the disease, to findout its relevance to treatment and to 
determine whether it can be used as a prognostic indicator. 
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 11. Lp(a) assessment can done in relation to other risk factors in 
peripheral arterial diseases. 
 12. Lp(a) assessment can be done in relation to stroke and other risk 
factors in stroke individuals. 
 13. To assess Lp(a) levels in other diseases where it is said to be 
increased stroke, Nephrotic syndrome, ESRD etc. 
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CASCADE OF REACTIONS INVOLVED IN FIBRINOLYSIS 
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CHART NO.5 
INFLUENCE OF Lp(a) ON FIBRINOLYSIS 
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A SCHEMATIC REPRESENTATION OF Lp(a) CATABOLISM 
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CHART NO.3 
ROLE OF Lp(a) IN TISSUE REPAIR AND FIBRINOLYSIS 
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Lp(a) AND ATHEROSCLEROSIS 
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Potential Mechanisms of Lipoprotein(a) (Lp(a)) pathogenecity. A variety of 
potential mechanisms that may account for the association of elevated Lp(a) 
levels with atherothrombotic disease has been described. These can be 
divided into those that are proatherogenic and those that are prothrombotic. 
(EC; Endothelial Cell, PA1-1; Plasminogen Activator Inhibitor, SMC; 
Smooth muscle cell, TFP1 ; Tissue Factor Pathway Inhibitor). 
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 ISOFORMS OF Apo(a) 
 
 
Designation No Molecular 
Mass (kDa) 
K IV Repeat 
Nos. 
Conc. of Lp(a) in 
mg/dl 
F 1 < 450 11 - 13 - 
B 1 ~ 500 14 - 16 61.7 
S 4 - - - 
S1 - ~ 550 17 - 19 34.4 
S2 - ~ 600 20 - 22 24.5 
S3 - ~ 650 23 - 25 10.2 
S4 - > 700 26 - 42 <5.7 
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FIGURE NO.3 
KRINGLE DOMAINS OF Apo(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    K-4  Kringle  4 
    K-5 - Kringle 5 
    T1-10 - Types 1-10 of K4 
    PD - Protease Domain 
 
Courtesy : Clinical Chemistry (Tietz) 
 
FIGURE NO.4 
STRUCTURE OF KRINGLE DOMAIN OF Apo(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1, 2, 3 - Crosslinking disulphide bridges 
Courtesy : British Heart Jor, 1991
 
 
 
FIGURE NO.6 
 
CATABOLIC PRODUCTS OF Lp(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   F1 - Fragment 1 
   F2  - Fragment 2 
   IV - Kringle IV 
   V - Kringle V 
   LDL - Low Density Lipoprotein 
   P - Protease domain 
 
Courtesy : American Journal of Cardiology, 1998 
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